The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Exhaled breath can reveal crucial insight into the microbiome
Pharma & Human Health

Exhaled breath can reveal crucial insight into the microbiome

MAY 12, 2023
DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device
Editor's Choice

DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device

MAY 10, 2023
Solarea Bio Announces First Close of Series B Financing Round
Finance

Solarea Bio Announces First Close of Series B Financing Round

MAY 9, 2023
SNIPR Biome’s data on drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology
Finance

SNIPR Biome’s data on drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

MAY 8, 2023
New discovery stops bacterial virus contamination
Infectious Disease & AMR

New discovery stops bacterial virus contamination

MAY 3, 2023
Recipharm will manufacture VOWST on behalf of Seres Therapeutics
Finance

Recipharm will manufacture VOWST on behalf of Seres Therapeutics

MAY 2, 2023
FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013
Clinical & Manufacturing

FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013

APR 28, 2023
Biomica Announces Closing of $20 Million Financing Round
Finance

Biomica Announces Closing of $20 Million Financing Round

APR 27, 2023
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™
Editor's Choice

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™

APR 27, 2023
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
Editor's Choice

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

APR 25, 2023
DSM agrees terms to acquire postbiotics pioneer Adare Biome
Biotics and Supplements

DSM agrees terms to acquire postbiotics pioneer Adare Biome

APR 19, 2023